Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ

Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ

This work investigated whether the anti-resorptive drugs (ARDs) zoledronic acid (Zol) and denosumab (Dmab) affect differently the levels of circulating immune cell subsets, possibly predicting the risk of developing medication-related ONJ (MRONJ) during the first 18 months of treatment. Blood sample...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Ilaria Roato, Lorenzo Pavone, Riccardo Pedraza, Ilaria Bosso, Giacomo Baima, Francesco Erovigni, Federico Mussano
Materialtyp: Artikel
Språk:English
Publicerad: MDPI AG 2023-10-01
Serie:Cells
Ämnen:
anti-resorptive drugs
denosumab
osteonecrosis
T cells
zoledronate
Länkar:https://www.mdpi.com/2073-4409/12/20/2430

Internet

https://www.mdpi.com/2073-4409/12/20/2430

Liknande verk